For individual treatment decisions in patients with metastatic prostate cancer (mPC), molecular diagnostics are increasingly used. Bone metastases are frequently the only source for obtaining metastatic tumor tissue. [...]

Background: Circulating tumour cell (CTC)ederived organoids have the potentialto provide a powerful tool for personalised cancer therapy but are restrained by low CTCnumbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA) to enrichCTCs from patients with metastatic prostate cancer (mPCa) and explored whether organoidsprovide a platform for ex vivo treatment modelling. [...]

Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomiclandscape. With the recent development of novel treatments, accurate stratification strategies are needed. [...]

Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. [...]